Table 4.
Selected studies evaluating the role of MRD to determine treatment.
Study | Patient population | Timing of MRD assessment | Technique |
---|---|---|---|
PERSEUS (NCT03710603) | TE-NDMM | 1-2 years into MT | NGS |
DRAMATIC (NCT04071457) | TE-NDMM | 2 years post MT | NGS |
MASTER (NCT03224507) | TE-NDMM | Post induction, ASCT, and consolidation | NGS |
EMN 20 (NCT04096066) | TIE-NDMM | 1-2 years of MT | NGS |
Abbreviations: TE-NDMM, transplant eligible newly diagnosed multiple myeloma; TIE-NDMM, transplant ineligible newly diagnosed multiple myeloma; MT, maintenance treatment; ASCT, autologous stem cell transplant; NGS, next generation sequencing; MRD, minimal residual disease.